The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma
Abstract
BACKGROUND: Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma. METHODS: This study, which was conducted by the North Central Cancer Treatment Group, evaluated 42 patients who were asymptomatic and had manifested, progressive prostate specific antigen (PSA) elevation with hormone therapy. Continued use of luteinizing hormone‐releasing hormone agonist was permitted; however, patients were ineligible if they had received other treatments for their disease in the preceding 4 weeks or if they had received a long‐acting antiandrogen therapy in the preceding 6 weeks. Patients were instructed to take 6 grams of green tea per day orally in 6 divided doses. Each dose contained 100 calories and 46 mg of caffeine. Patients were monitored monthly for response and toxicity. RESULTS: Tumor response, defined as a decline ≥ 50% in the baseline PSA value, occurred in a single patient, or 2% of the cohort (95% confidence interval, 1–14%). This one response was not sustained beyond 2 months. At the end of the first month, the median change in the PSA value from baseline for the cohort increased by 43%. Green tea toxicity, usually Grade 1 or 2, occurred in 69% of patients and included nausea, emesis, insomnia, fatigue, diarrhea, abdominal pain, and confusion. However, six episodes of Grade 3 toxicity and one episode of Grade 4 toxicity also occurred, with the latter manifesting as severe confusion. CONCLUSIONS: Green tea carries limited antineoplastic activity, as defined by a decline in PSA levels, among patients with androgen independent prostate carcinoma. Cancer 2003;97:1442–6. © 2003 American Cancer Society. DOI 10.1002/cncr.11200
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Why drinking green tea could prevent cancer
Jankun, J., Selman, S. H., Swiercz, R., & Skrzypczak-Jankun, E. (1997) · Nature · doi:10.1038/42381 · Cited by 718
Polyphenols as cancer chemopreventive agents
Stoner, G. D., & Mukhtar, H. (1995) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240590822 · Cited by 604
Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols
Gupta, S., Hastak, K., Ahmad, N., Lewin, J. S., & Mukhtar, H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171326098 · Cited by 486
Cancer-Preventive Effects of Drinking Green Tea among a Japanese Population
Imai, K., Suga, K., & Nakachi, K. (1997) · Preventive Medicine · doi:10.1006/pmed.1997.0242 · Cited by 352
Paschka, A. G., Butler, R., & Young, C. Y.-F. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00084-6 · Cited by 288
Self-citationPhase I Trial of Oral Green Tea Extract in Adult Patients With Solid Tumors
Pisters, K. M. W., Newman, R. A., Coldman, B., Shin, D. M., Khuri, F. R., Hong, W. K., Glisson, B. S., & Lee, J. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1830 · Cited by 243
Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation.
Lamy, S., Gingras, D., & Béliveau, R. (2002) · PubMed · Cited by 203
Black tea consumption and cancer risk: A prospective study
Heilbrun, L. K., Nomura, A. M. Y., & Stemmermann, G. N. (1987) · British Journal of Cancer · doi:10.1038/bjc.1986.226 · Cited by 153
Confidence Intervals for a Binomial Parameter Based on Multistage Tests
Duffy, D. E., & Santner, T. J. (1987) · Biometrics · doi:10.2307/2531951 · Cited by 143
Cited by
Doyle, C., Kushi, L. H., Byers, T., Courneya, K. S., Demark-Wahnefried, W., Grant, B., McTiernan, A., Rock, C. L., Thompson, C., Gansler, T., et al. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.6.323 · Cited by 950
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Targeting Multiple Signaling Pathways by Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate
Khan, N., Afaq, F., Saleem, M., Ahmad, N., & Mukhtar, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3636 · Cited by 820
Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways
Ramos, S. (2008) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700326 · Cited by 696
Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention
Ramos, S. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.11.004 · Cited by 617
Metadata
- Authors
- Jatoi, A., Ellison, N., Burch, P. A., Sloan, J. A., Dakhil, S. R., Novotny, P., Tan, W., Fitch, T. R., Rowland, K. M., Young, C. Y. F., & Flynn, P. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-03-03
- Volume
- 97
- Issue
- 6
- Pages
- 1442-1446
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2009686658
- Cited by
- 284
- References
- 12
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. https://app.cochat.ai/papers/10.1002/cncr.11200
- The paper
- Jatoi, A., Ellison, N., Burch, P. A., Sloan, J. A., Dakhil, S. R., Novotny, P., Tan, W., Fitch, T. R., Rowland, K. M., Young, C. Y. F., & Flynn, P. J. (2003). A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. https://doi.org/10.1002/cncr.11200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.